Reassessing the Practical Utility of Colonoscopy: Insights from the NordICC Clinical Trial
##1: Prestige of the Gold Standard and Evidence Gap Over the past two decades, colonoscopy has been regarded as the gold standard for colorectal cancer prevention. Policymakers and clinicians have been confident, based on observational studies and modeling data, that colonoscopy would reduce cancer incidence and mortality by more than 50%. However, this strong belief has rested on a fundamental problem: a lack of definitive evidence from large randomized controlled trials (RCTs).
##2: Unexpected Findings Revealed by the NordICC Trial
The NordICC (Northern-European Initiative on Colorectal Cancer) trial directly compared a colonoscopy screening arm with usual care, filling this evidence gap. The results were striking. Colonoscopy screening reduced colorectal cancer incidence by approximately 18%, but the anticipated reduction in colorectal cancer mortality did not reach statistical significance. This indicates a substantial discrepancy with the optimistic estimates reported by earlier observational research.
##3: Quality of Screening and Adherence as New Variables These outcomes highlight not merely the limitations of the procedure itself, but the critical importance of patient adherence and the quality of the screening process in real‑world clinical settings. In the NordICC trial, the proportion of participants who actually underwent colonoscopy was lower than expected, and variations in endoscopist adenoma detection rates (ADR) likely influenced the results. Therefore, maximizing the benefit of colonoscopy requires strategies that go beyond increasing the number of examinations to ensure high‑quality performance and encourage voluntary patient participation.
##4: Paradigm Shift Toward Personalized Screening The study calls for a move away from a “one‑size‑fits‑all” screening strategy toward a personalized approach that accounts for individual risk and cost‑effectiveness. By resetting realistic expectations for colonoscopy, we can avoid harms and waste associated with over‑screening, and develop more precise guidelines. Coupled with long‑term follow‑up, this will allow early‑detection systems for colorectal cancer to mature on a data‑driven basis.
For more than two decades, colonoscopy has been promoted as the gold standard for colorectal cancer screening. Policy makers and professional societies have largely accepted observational data and modelling estimates that suggest that colonoscopy cuts colorectal cancer incidence and mortality by at least 50%.1 Against this backdrop of strong belief but insufficient randomised evidence, the NordICC randomised clinical trial of colonoscopy screening versus usual care for the primary endpoints of colorectal cancer incidence and mortality has been uniquely important.
This dataset reconfirms the 'grade of evidence' that underpins health‑policy formulation. By supplementing the limitations of observational data with RCT evidence, it provides a high‑quality source that can correct selection bias when AI systems learn from medical policy or clinical guideline data.